Month: March 2014

CHIP PI Lisa Eaton Has Been Awarded a New Supplement

This application is being submitted in response to RFA-MH-14-140 (R01): “Revision Applications for Research on Assessing the Role of Stigma in HIV Prevention and Care.” The proposed project will examine the role of stigma as a social-structural barrier to accessing STI/HIV treatment and retention in care among African American men who have sex with men (AAMSM) who are recently diagnosed with STI/HIV. AAMSM represent 70% of all new HIV infections among AA men and comprise a disproportionately high 36% of the incident HIV infections among all MSM. Likewise, we observe disproportionately high rates of non-HIV STI among AAMSM and evidence suggests a surge in primary and secondary syphilis infection among these men. Experiences with stigma have been identified as a critical and powerful deterrent to seeking health care for STI/HIV related treatment, yet little is understood about how the mechanisms of stigma manifest themselves during the course of accessing health care.

New Grants Awarded to CHIP Principal Investigators

Three CHIP Principal Investigators have been awarded new grants:

Dr. Rebecca Ferrer, PhD, Speaking at CHIP Thursday, March 27, 2014

Please join us for the next event in the Spring 2014 CHIP Lecture Series!

“Affective Science Perspectives on Cancer Prevention and Control Decision-making”

Rebecca Ferrer, NCI

Thursday, March 27, 2014

12:30 – 1:30pm



The lecture will take place in Video Conference Room 204 on the second floor of the Ryan Building at 2006 Hillside Road at the University of Connecticut in Storrs. For directions and maps, see

Live Stream

You can view this talk streamed live during or after the lecture at Live webcast viewers may submit questions in real time; simple instructions are posted at

About the Speaker

Rebecca FerrerRebecca Ferrer is a Health Scientist/ Program Director at the National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS), Behavioral Research Program (BRP), Basic Biobehavioral and Psychological Sciences Branch (BBPSB). She earned her Doctorate in Social Psychology from the University of Connecticut in 2009, with a certificate in Quantitative Methods, and holds a Bachelor of Science degree in Decision Science from Carnegie Mellon University. She completed a Post-Doctoral Cancer Research and Training Award Fellowship in the Office of the Associate Director (OAD)in 2011. Rebecca’s program of research centers on social psychological processes in health-related judgment and decision making, and behavior change. She is particularly interested in examining the associations among emotion and cognition, including how emotion might moderate the association between cognitions (including social cognitions) and health behavior. This program of research reflects a multidisciplinary approach, drawing from the fields of decision science, social psychology, and health psychology. Her work has focused primarily on cancer prevention behaviors such as nutrition, physical activity, and cancer screening, as well as HIV preventive behaviors such as condom use. She is also actively involved in the NCI’s Theories Project, which aims to identify and execute research that will further the field of health behavior theory, including critical thought about and comparison of theory, integrative theory testing, and integration of theory into health behavior change interventions.

About the CHIP Lecture Series

The CHIP Lecture Series provides an invaluable forum for researchers – at CHIP, throughout the UConn community and beyond – to learn about new works in development.

More information available at:

CHIP Affiliate William Zempsky Featured in Hartford Courant

CHIP Affiliate William Zempsky was featured in a story in the Hartford Courant on February 21, 2014, titled, “Doctor’s Dilemma: Dosing Medical Marijuana.”

An excerpt from the piece:

But it’s not like any other pharmaceutical, Zempsky and other physicians have pointed out. It doesn’t have federal approval or the guidelines that come with it, and there are none of the large-scale clinical trials that other medications go through. The drug’s active ingredients haven’t been isolated so patients cannot know exactly what — and how much of them — they are consuming.

“With marijuana, there’s no homogeneity,” Zempsky said. “It’s a mixture of several different things, and there are impurities. If it was inspected the way they do other drugs, they would never allow it on the market.”